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Background: BCG-RIVM strain was used in many treatment protocols for non-muscle invasive bladder cancer only
as induction courses. Cho et al. (Anticancer Res 2012) compared BCG-RIVM induction and 'standard' maintenance
(Lamm et al., J Urol. 2000) to mitomycin C. They found no statistically significant differences regarding disease
recurrence and progression. The purpose of our study was to determine the efficacy & tolerability of this specific
BCG RIVM strain, using six-weekly, induction course and single monthly instillations as maintenance for one year,
in high risk recurrent, multifocal low grade and multifocal high grade pTa/pT1, CIS transitional cell carcinoma of
bladder.
Methods: From 2003 - 2012, BCG-naive patients treated with intravesical BCG-RIVM for high-risk multifocal NMIBC
were identified. Transurethral resection of bladder tumor (TURBT) and re-staging TURBT within six weeks, was done
for accurate staging and complete elimination of disease. A six-weekly induction course, started 2-3 weeks after the
last TURBT, followed by monthly maintenance protocol for one year. Recurrence, progression, cystectomy free
survivals, cancer specific and over-all survival were determined.
Results: Sixty evaluable patients - median age 63, median follow-up 3.98 years. Forty-two patients (70%) completed
BCG-RIVM treatment as planned. BCG termination was necessary in 18 patients (30%). Recurrence occurred in
16 patients (26.7%) at a median follow-up of 24.2 months while progression occurred in five patients (8.3%) at a
median follow-up of 33 months. Recurrence-free survival and progression-free survival rates were 73% and 92%
respectively. Cystectomy was performed in seven patients (12%) with a cystectomy-free survival of 88%. There were
no cancer specific deaths. Two patients died of other causes (3.3%). The overall survival rate was 97%.
Conclusions: Our study is the first to show the clinical efficacy and tolerability of BCG-RIVM strain in the management
of high risk NMIBC when given in a schedule of six-weekly induction with monthly maintenance for one year. Our
maintenance protocol, achieved equivalent recurrence-free, progression-free, disease specific survival and overall
survival to the reported literature and the more intense three-years South West Oncology Group (SWOG) protocol.
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Bacille Calmette-Guerin for urothelial carcinoma has
been the most successful use of immunotherapy to date
and represents the standard of care for urothelial CIS
and superficial bladder tumors [1]. Although BCG has
been in use for over 35 years, the optimal dose and in-
stillation schedule remains unclear. Nevertheless several
meta-analyses showed the overall superiority of intravesical
BCG with some form of maintenance therapy over chemo-
therapy in terms of recurrence-free and progression-free
survival rates [2-5]. The two Dutch trials [6,7] that failed to
show superiority of RIVM or Tice BCG over mitomycin C,
could be explained by a sub-optimal BCG schedule, re-
cruitment of high percentage of low risk patients, the type
of BCG strain used or short follow-up. Other trials [8] that
showed no advantage of maintenance BCG over induction
course alone, may also be related to the BCG maintenance
schedule, which may have t been sub-optimal for immuno-
logical boosting [9].
One of the major obstacles to a meaningful comparisons
between different trials has been the adoption of variable
maintenance schedules and BCG doses. Lamm et al. [10]
advocated the use of an intense protocol of maintenance
that he described as, "the current gold standard", which
consisted of intravesical BCG - standard dose - every week
for 3 weeks given at 3, 6, 12, 18, 24, 30 and 36 months
from initiation of induction therapy; however, only 16% of
patients completed the treatment protocol as planned.
When designing a maintenance protocol, two main fac-
tors should be considered: efficacy and compliance. Both
of these factors depend on: BCG strain, dose volume, dur-
ation of treatment, total number and frequency of instilla-
tions [11].
Several different BCG strains are currently available for
intravesical instillation [3,4,12]. These strains show differ-
ences in its phenotype, antigenicity and immune reactivity
which may influence their antitumor activity, toxicity and
clinical efficacy [13]. Despite BCG strain differences, very
few studies were conducted to compare their efficacy, op-
timal dose and toxicity in the clinical setting.
Although BCG-RIVM is the third most commonly
used BCG strain world-wide after Tice and Connaught
[14], for unclear reasons, it is one of the less frequently
used BCG strains in the reported clinical trials.
Since no clinical assumptions can be made regarding
the individual BCG strain, unless efficacy and tolerability
is proven in the clinical setting [5], we reviewed our ex-
perience in the use of this specific BCG -RIVM strain,
with an induction course of one instillation every week
for 6 weeks and a single monthly instillation as mainten-
ance for one year, to determine its tolerability and effi-
cacy in preventing recurrence, progression and cancer
specific death and to determine the cystectomy-free sur-
vival and over-all survival.Methods
From January 2003 to December 2012 all patients who
were treated with intravesical BCG-RIVM therapy at our
institution were reviewed. All patients had histologically
proven transitional cell carcinoma (TCC) of the urinary
bladder pTa/pT1 with or without concomitant carcin-
oma in situ (CIS) or primary carcinoma in situ (2002
TNM classification of urinary bladder cancer and 2004
WHO grading system). Only two patients had Lympho-
vascular invasion. According to our institution's clinical
practice guidelines, intravesical BCG-RIVM therapy was
offered to all patients who were BCG naive, had high
grade (TCC) Ta/T1 and CIS and to patients with low
grade TCC but who were considered at high risk of recur-
rence and/or progression (multifocal and recurrent TCC).
Complete transurethral resection of the bladder tumor
(TURBT) and re-staging TURBT within six weeks prior to
starting intravesical BCG therapy was done to all patients
(including pT1 and pTa) to eliminate any residual tumor
and confirm the stage of the disease. All patients had basic
blood tests & computed tomography (CT) scan for chest,
abdomen and pelvis and restaging CT scans & bone scan
prior to radical cystectomy.
Ethical approval
The study was approved by the King Hussein Cancer
Center Institutional Review Board (No. 12 KHCC 70).
Patients consent
Written informed consent to intravesical BCG therapy was
obtained from all patients in this study. The consent was
obligatory and a standard requirement in accordance with
King Hussein Cancer Center Clinical Practice Guidelines.
BCG protocol and treatment schedule
Intravesical BCG therapy was started 2 - 3 weeks after the
restaging TURBT. The BCG strain used was: Seed RIVM
(derived from seed 1173 -P2, 2 × 10 [8] -3 × 10 [9] viable
units). Marketing authorization Holder and Manufacturer:
Medac, Gesellschaft fur, klinischeSpezialpraparatembH,
FehlandtstraBe 3, D-20354 Hamburg, Germany. BCG-
RIVM strain was the only strain available at our institu-
tion. The choice was made on the basis of a competitive
price, the commitment by the manufacturing company to
ensure a steady supply of the medicine and on the pre-
sumption (at the time) that all commercially available
BCG strains were equally effective.
The BCG-medac powder was re-suspended with 50 ml
of 0.9% normal and introduced into the bladder via a 12
French urethral catheter.
Patients were instructed to hold on the medicine in
the bladder for two hours and to lie on their back, right
side, left side and face-down for 30 minutes each before
voiding. They were also instructed to refrain from oral
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treatment session. Induction course consisted of one in-
stillations every week for 6 consecutive weeks, while
maintenance course consisted of one instillations every
month for one year in patients with no evidence of dis-
ease after the re-staging TURBT. Full BCG dose was
used for both induction and maintenance therapy.
Cystoscopy schedule
Cystoscopy +/- TURBT was done every three monthly
for the first two years, then every six monthly for the
next two years, then annually thereafter. If recurrence oc-
curs then the clock for cystoscopy is re-set at every three
months.
Definitions of BCG responses
BCG resistance: defined as persistent disease at three
months following induction course. BCG refractory: fail-
ure to achieve disease-free state at six months because
of persistent or rapidly recurring disease. BCG relapse:
recurrence of disease after six months of disease-free
state. BCG intolerance: when patient discontinue treat-
ment because of severe lower urinary tract side effects;
(If this occurs during the induction course then it would
not be considered BCG failure as treatment was not
actually given). BCG failure: persistence of high grade
disease at six months (or at three months if the initial
tumor was pT1G3), any worsening of disease parameters
(higher grade, stage, number of recurrences or appearance
of CIS) or detection of pT2 disease during follow-up [15].
Progression was defined in this study as any worsening
of disease parameters including change of pTa low grade
to high grade or to pT1 or detection of pT2 disease dur-
ing follow-up.
Salvage therapy
Cystectomy was offered to patients who progressed,
developed worsening disease parameters, were BCG re-
sistant or BCG refractory. However for patients who de-
clined cystectomy, intravesical therapy with MMC was
offered. MMC treatment protocol was 40 mg in 40 ml of
0.9% normal saline one instillation every week for six
weeks then one instillation every month for six months
and a single instillation after every TURBT.
Statistical method
Patients' characteristics such as age group, gender, hist-
ology and others were presented in terms of counts and
percentages as shown in the tables and figures of this
study. Treatment outcome (recurrence and progression)
was compared among the treatment groups using Log
rank test. Survival and event-free survival were presented
by Kaplan-Meier curves showing their three/five year
rates and standard error. Hazard ratios (HR) and theircorresponding 95% confidence intervals (CI) were cal-
culated to compare the risk between the different categor-
ies of each factor. All analyses were performed using: SAS
version 9.1 (SAS Institute Inc, Cary, NC).
Results
Sixty evaluable patients with a median age of 63 years
(range 37 - 81; mean 61.7 years) were available. Median
follow up was 3.98 years (range 8.28 - 93.6 months,
mean 4.1 years). According to histological grade the
study population of this cohort, consisted of two groups;
group 1: 37 patients (61.7%) of 'high risk' low grade,
recurrent and multifocal TCC and group 2: 23 patients
(38.3%) of high grade multifocal TCC. In 55 out of 60
patients (92%) the tumors were papillary, while primary
CIS or concomitant CIS and papillary were present in 5
out of 60 (8%). A great emphasis in this study was
placed on complete elimination of disease by re-staging
TURBT prior to start of intravesical BCG therapy, close
endoscopic surveillance and early counseling for radical
cystectomy at the earliest sign of BCG failure.
Forty two out of 60 patients (70%) completed the intra-
vesical BCG treatment protocol as planned, while BCG
termination was necessary in 18 out of 60 patients (30%).
The mean, median and minimum number of BCG instilla-
tions were 15.7, 18 and 3 respectively. In 16 patients,
the terminations were related to sever lower urinary
tract symptoms. BCG intolerance occurred in 11 of 18
patients (61.1%); BCG refractory state occurred in 3 of 18
patients (16.7%) and BCG resistance and sepsis in 2 of
18 patients each (11.1%). Complete demographic data are
presented in (Table 1). The two patients who developed
BCG sepsis, defined as: systemic BCG infection with per-
sistent high grade fever and positive blood cultures for
BCG; they required anti-tubercular therapy and further
intravesical BCG was discontinued.
Forty four out of 60 patients (73.3%) remained free of
recurrence during the entire follow up period while 16
out of 60 patients (26.7%) had recurrences at different
time; five patients in the first year, 10 patients at 1 - 5
years and only one patient had a recurrence after five
years. Median time to recurrence was 24.2 months (range
3.12 - 78). Recurrences occurred with equal frequency in
the low grade and high grade groups, at 27% (10 of 37 pa-
tients) and 26% (6 of 23 patients) respectively (Figure 1).
For low grade group, the recurrence-free survival rates
at three and five years were 74% and 69% respectively,
while the values for the high grade group were 69.9% for
both periods. There was no statistical difference between
the two groups (p = 0.88). When all grades where com-
bined the three and five year recurrence-free survival rates
were 72.5% (95% CI: 57.67 - 82.98, SE: +/- 6.4) and 68.9%
(95% CI: 52.9 - 80.5, SE: +/- 7.05) respectively. Analysis of
Kaplan-Meier curves for the recurrence-free survival of
Table 1 Demographic data of study patients
N (Percent %)






No. of tumors 2-7 57(95.0%)
>8 3(5.0%)
Stage Primary CIS 2(3.3%)
T1 24(40.0%)
Ta 34(56.7%)
Grade High grade 23(38.3%)
Low grade 37(61.7%)
Histology Papillary 55(91.7%)
Concomitant CIS and papillary 3(5.0%)
Primary CIS 2(3.3%)
BCG BCG Complete 42(70%)
BCG Termination 18(30%)




Median Maximum Minimum Mean
Age (Years) 63 81 37 61.7
Cigarette pack-year 60 150 10 55.4
No. of BCG installation 18 18 3 15.7
Follow up time (Years) 3.98 7.8 8.28 months 4.1
Figure 1 Kaplan-Meier recurrence free survival curve of all grades and 3 & 5 year survival rates.
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separately (Figure 1) showed that most recurrences (in 14
patients) occurred within the first three years, while
recurrence occurred in one patient each at the 4th and
6th year.
Progression occurred in five patients (8%) between one
and four years after the start of BCG therapy. Median
time to progression was 33 months (range 13.9 - 43.2).
Three patients progressed from pTa/pT1 low grade to
pT1G3 and only two patients progressed from T1G3 to
pT2 disease; interestingly, both of these patients had
Lymphovascular invasion at their initial histology. For
the low grade group, the progression-free survival rates
at three and five years were 96.9% and 92.4% respect-
ively, while the values for the high grade group, were
88.7% and 78.8% respectively (Figure 3). There was no
statistical difference between the two groups (P = 0.19).
The three and five years progression-free survival rates
for all grades combined were 93.9% (95% CI: 82.4 - 98,
SE: +/- 3.4) and 87.9% (95% CI: 72.8 - 94.9, SE: +/- 5.2) re-
spectively. Analysis of Kaplan-Meier curves for progression-
free survival for both groups combined (Figure 4) and for
the two groups separately (Figure 3) showed that all pro-
gressions occurred within the first 4 years. Although the
five year progression-free survival rate of low grade and
high grade groups were 92.4% and 78.8% respectively, with
a hazard ratio of 3.07 (Figure 3), it did not reach statistical
significance. However the number of progressions were
too few for definitive conclusion - two out of 37 patients
(5%) in the low grade group and three out of 23 patients
(13%) in the high grade group.Figure 2 Kaplan-Meier recurrence free survival curve of all patients.During follow up, patients who developed progression,
BCG resistance, BCG refractory or BCG relapse were
counseled and offered radical cystectomy. In this cohort
radical cystectomy and bilateral pelvic lymphadenectomy
- standard template - was performed in seven patients
(12%), all within the first three years. The mean and me-
dian lymph node yield was 16 (range 8 - 29). Lymph
nodes were negative in all patients. The final histology
of the radical cystectomy specimens were as follows:-
2 patients: pT2 N0, 2 patients: CIS N0, 2 patients: pT0
N0 (T1 G3 tumors were resected prior to the radical
cystectomy) and one patient: pTa G3 N0. The cystectomy-
free survival rate was 88% (Figure 5). All cystectomy pa-
tients are currently alive; six patients without evidence of
disease but one patient, during follow-up, developed
retroperitoneal lymph node metastasis and was treated
with systemic chemotherapy. One patient who progressed
to pT2 disease (at 30 months of follow up) had radiologic
evidence of pulmonary nodules, pelvic and retroperitoneal
lymphadenopathy suggestive of metastasis; he was treated
with systemic chemotherapy and is still alive at last
follow-up with stable disease. Of the 12 patients who had
recurrences but declined cystectomy at first sign of BCG
resistance or refractory state, six patients were treated
with intravesical MMC according to the above described
protocol and six patients were kept on surveillance cystos-
copy as they refused any form of intravesical therapy. Fur-
ther recurrences occurred in eight of the 12 patients, of
which one patient had radical cystectomy, two patients
continued on MMC and five patients were kept on sur-
veillance cystoscopy (Table 2).
Figure 3 Kaplan-Meier progression free survival curve of all grades. Please note that low grade was also high risk.
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up of 4.1 years and the overall survival was 97% (Figure 6).
Current status
At last follow up, 58 patients (96.7%) were alive. Two
patients died (3.3%), one patient from myocardial infarc-
tion while the other patient died from bacterial sepsis
secondary to perforated neobladder. The perforation oc-
curred 11 months after the radical cystectomy with no evi-
dence of recurrent disease; both of these deaths occurred
around the 4th year of follow up. There were no cancer
specific deaths in this cohort (Figure 1). The three and five
year overall survival rates were estimated at 100% (95%Figure 4 Kaplan-Meier progression free survival curve of all patients.CI: NA and SE: NA) and 92.7% (95% CI: 73.7 - 98.2, SE:
+/- 4.98) respectively.
Discussion
Several studies have established the superiority of intrave-
sical BCG with maintenance over chemotherapy in inter-
mediate and high-risk NMIBC with regard to long-term
tumor recurrence, progression and mortality [9,10,16].
However, Malmstrom et al. [4] reported on an individ-
ual data meta-analysis of nine trials with 2820 patients,
comparing long-term outcome of intravesical MMC ver-
sus BCG in NMIBC. All The trials included in that meta-
analysis had some sort of maintenance MMC. The authors
Figure 5 Kaplan-Meier cystectomy free survival curve during the entire follow-up period.
Table 2 Summary of follow-up results
Total number of patients 60
Disease recurrence No 44(73.3%)
Yes 16(26.7%)
Histology of recurrence T1-High grade 4(25.0%)
Ta-High grade 2(12.5%)
Ta-Low grade 10(62.5%)
Salvage therapy Cystectomy 4(25.0%)
Mitomycine C 6(37.5%)
Surveillance cystoscopy & TURBT 6(37.5%)
Further recurrence No 52(86.7%)
Yes 8(13.3%)
Histology further recurrence T1-Low grade 1(12.5%)
Ta-Low grade 7(87.5%)
Further Salvage therapy Cystectomy 1(12.5%)
Mitomycine C 2(25%)
Surveillance cystoscopy & TURBT 5(62.5%)
Disease progression No 55(91.7%)
Yes 5( 8.3%)
Histology of progression T1-High grade 3(60.0%)
T2 2(40.0%)
Further Salvage therapy Cystectomy 2(40.0%)
Surveillance cystoscopy & TURBT 2(40.0%)
Systemic chemotherapy 1(20.0%)
Outcome Alive 58(96.7%)
Death from other cause ( one, myocardial infarction and one, sepsis secondary to perforated neobladder) 2(3.3%)
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Figure 6 Kaplan-Meier overall survival curve.
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BCG was needed to be more effective than MMC. Prior
intravesical chemotherapy was not a confounder, and did
not bias the results in favor of BCG. However there were
no statistically significant differences regarding progres-
sion, overall survival and cancer specific survival between
the two treatments.
Although a majority consensus suggests that BCG with
maintenance is superior to MMC in recurrence free sur-
vival, the debate is likely to continue, regarding progres-
sion and cancer specific survival, unless researchers
address in their studies, the type of the BCG strain used
among other variables.
The emphasis on the use of BCG with maintenance in
the treatment of NMIBC was further highlighted by
Saint et al. [2] who reported on a meta-analysis of 24 tri-
als with some form of BCG maintenance involving 1685
patients. They found that, at a mean follow-up of 41 months
the average recurrence free survival rate was 70%, the
average progression rate was 8% and the disease-free spe-
cific survival rate was 91%. Our results are in concordance
with the above meta-analyses and others (Table 3). The






Lamm 2000 [9] 192 98 40 24
Peyromaure
2003 [26]
57 53 42 23
Pansadoro
2003 [27]
86 91 35 14
Yoo 2012 [18] 92 43 35.6 20
Present series 60 47.8 26.7 8.3study were, 72.5% and 68.9% respectively, and the
progression-free survival rates for the same periods were,
93.9% and 87.9% respectively. However, it is important to
note that our cohort are high grade and low grade with
'high risk' for recurrence and progression because of the
recurrent and multifocal nature of the disease (Table 1);
thus accounting for a similar biological behavior in terms
of recurrence and progression rates for the two treatment
groups.
In our study only two patients progressed to muscle
invasive disease during the follow-up period. One patient
underwent immediate Radical cystectomy, while in the
other patient, re-staging studies showed pulmonary nod-
ules and retroperitoneal lymphadenopathy suggestive of
metastatic disease and was treated with chemotherapy.
Both of these patients had Lymphovascular invasion at
the initial histology suggestive of a bad prognosis.
However, Cho et al. [17] reported in their series, the
presence of Lymphovascular invasion in 29 out of the 107
patients (27%), but made no reference to this finding in
the analysis of the results. In fact European Association of
Urology Guidelines makes no reference to Lymphovascular
invasion in the management of NMIBC.maintenance protocols
n % Disease specific
survival
BCG strain Maintenance protocol
83 Connaught 3 weekly at 3, 6, 12, 18, 24, 30, 36
88 Pasteur 3 weekly at 3, 6, 12, 18, 24, 30, 36
94 Pasteur Every 2 weeks × 6, every month × 6,
every 3 months × 6
85.3 Tice Monthly for 12 months
100 RIVM Monthly for 12 months
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monthly maintenance protocol (BCG-Tice strain) for
one year, and showed similar median recurrence-free
(RSF) and survival rates to that of the SWOG protocol
(BCG-Connaught strain) [9]. In the SWOG study, the
median RFS was 76.8 months with 83% 5-year survival
rate, and for Yoo et al. [18] study the corresponding
figures were 87 months and 85.3%. Our study also
achieve similar results with a protocol of monthly main-
tenance (BCG-RIVM) for one year. In our series the over-
all survival was 97% with no cancer specific deaths and an
even lower progression rates (8.2%), compared to SWOG
[9]and Yoo series [18] which were (24%) and (20%) re-
spectively. This difference could be related to the different
BCG-RIVM strain in our study, racial (Jordanian popula-
tion) or to our protocol which included a mandatory re-
staging TURBT prior to BCG therapy.
Cho et al. [17] compared the efficacy of BCG-RIVM
and MMC in 107 Korean patients with pT1G3 bladder
cancer. The BCG arm consisted of 53 patients, of which
26 were treated with only 6-weekly induction course,
and 27 patients treated with similar induction course plus
three once-weekly maintenance at 3, 6, 12 and 18 months;
while The MMC arm consisted of 54 patients, of which 29
were treated only with (30 mg) weekly instillations for 6
weeks, and 25 patients with similar 6-weekly instillations
plus monthly instillation for one year. The authors then
combined the data of both groups in each treatment arm
for analysis. They found that the 2-year recurrence-free
rate for BCG and MMC to be 45.7% and 52.1% respect-
ively, while progression occurred in 9.4% and 7.4% of pa-
tients respectively. The authors concluded that there was
no statistically significant difference between the two
treatment arms in terms of recurrence and progression
rates. The authors did not report the compliance rate in
the BCG maintenance group. In our view, the results
should be interpreted with caution, since half of the
patients in each of the treatment arms were treated with
induction courses only, which is now considered sub-
optimal therapy [19] and would have undoubtedly, diluted
the results. A more meaningful analysis would have been,
a comparison between the two maintenance groups.
The fact that, so many treatment protocols existed in
just as many trials confirms that the ideal protocol is still
unknown. The mechanism of action of intravesical BCG
is incompletely characterized. However BCG-induced
anti-tumor activity, depends on both, local and systemic
immunological responses [20]. After initiating intravesi-
cal BCG instillation, immune stimulation generally peaks
at 6 weeks. However with subsequent instillations (as in
maintenance therapy) the immune stimulation peaks at
3 weeks, and is suppressed at weeks 4, 5, and 6 [9,11]. This
would explain the negative results of maintenance proto-
cols that used repeated six-weekly instillations. However,whether the ideal 'immune stimulation schedule' is, every
month, every 3 months or otherwise, remains to be deter-
mined for the individual patient and for the specific BCG
strain in the clinical setting. Thus, the 'gold standard' for
BCG maintenance schedule is yet to be determined.
BCG intolerance and the development of complica-
tions are important factors in further determining the
ideal maintenance protocol. BCG tolerance appears to
be relate to dose, BCG strain, frequency and total num-
ber of instillations. Badalament et al. [21] reported a 36%
compliance - Pasteur strain - on a schedule of one instil-
lation every month for 24 months, and in Palou et al.
series [22] this value was 33.8% (Connaught strain) on a
schedule of 6 instillation every 6 months for 2 years.
However, in Akaza et al. series [8] the compliance was
65.5% using 1/2 dose of BCG Tokio strain at one instil-
lation every month for 1 year.
In our study, 70% of patients completed the 'once monthly
maintenance' protocol while in Yoo et al. [18] study (BCG
Tice strain) using a similar protocol, 100% of patients
completed the treatment as planned. Cho et al. [17] al also
reported a 100% patient's compliance using BCG-RIVM,
on a maintenance protocol based on SWOG recommen-
dation but for only 18 months. Clearly, such variable re-
sults, reported from different geographical locations may
also have a racial explanation among others.
To improve BCG tolerance without compromising ef-
ficacy, not only frequency and number of instillations, but
also dose reduction was considered. Saint et al. [2] ana-
lyzed the impact of reduced BCG dose (1/3 - 1/2 dose) in
10 trials, seven of which had some form of maintenance
therapy, and found that, at a mean follow-up of 40 months,
the average recurrence-free survival rate was 62%, the aver-
age progression rate was 11% and disease-free specific sur-
vival rate was 90%. The authors concluded that low dose
and full schedules, when maintenance therapy is used, gave
similar results for recurrence and progression. The meta-
analysis further confirmed that maintenance therapy was
better than first induction courses as regards recurrences
and better than first and second induction courses as
regards progression. On the other hand, low dose schedule
in first or second induction courses should be considered
carefully as there were reports of 25% progression in high
risk tumors, suggesting that high-risk tumors and CIS
would not benefit from dose reduction [2].
Our study is the first in which this specific BCG RIVM
strain was used in the form of induction with monthly
maintenance protocol for one year in patients with high
grade and high risk low grade NMIBC. The treatment
protocol was well tolerated. However, two patients de-
veloped BCG sepsis requiring discontinuation of therapy
and initiation of antituberculous treatment. The majority
of complications which were encountered in our study
were the less serious lower urinary tract symptoms. BCG-
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tions compared with other BCG strain (A. Frappier, Tice,
Connaught and Pasteur) (10). However, Strock et al. [23]
reported a 1.8% (of 858 patients), unusual solitary BCG
ulceration (10 mm), exclusively in males, and seen more
frequently with BCG-RIVM than Tice. We have not en-
countered this complication.
In our study, close surveillance, re-staging TURBT and
early counseling with view to radical cystectomy for BCG
failures were important tools in preventing cancer specific
deaths. This is evident by the finding of pT2 in only two
of seven patients and negative lymph nodes on the final
histology of all cystectomy patients. Some would argue
that this is an over treatment, however, evidence suggests
that patients who recurred within a year of initial BCG
therapy did significantly worse, with disease-free rates of
34-43% at 24 months, indicating that additional immuno-
therapy may not be appropriate [24]. In a more recent
study, a decrease in survival was reported in patients
cystectomised for pT1 disease [25] suggesting that it could
be related to the more common use of intravesical ther-
apy, thus, delaying radical surgery.
In our study five of the seven cystectomies were done
within the first two year (Figure 2). Radical cystectomy
was done in 12% of our patients. Our result is in con-
cordance with that published in the literature which
ranged from 9% - 26% [10,26,27].
BCG-RIVM strain was introduced into clinical practice
in 1986 after its proven safety and efficacy in an animal
study [28]. Over the ensuing 10 years or so, several stud-
ies were reported most notably by the Dutch South-East
Cooperative Urological group and to a lesser extent by
the European Organization for Research and Treatment
on Cancer- Genitourinary Group (EORTC), using BCG -
RIVM strain as induction courses only. However, this
specific BCG strain was less frequently used in subse-
quently published trials compared to other BCG strains
Our interest in this specific BCG-RIVM strain stems
from the fact that it is the main BCG strain used in our
country (Jordan) for intravesical therapy of NMIBC. Thus,
determination of its efficacy and tolerability in the clinical
setting with a schedule of 'induction with maintenance'
was mandatory, since such data is lacking in the literature.
Clinical evidence suggests that certain BCG strains are
more effective than others [6]. Research on two bladder
cancer cell lines using BCG strain S4-Jena and BCG-Tice
to assess their efficacy on cancer cell lines proliferation
and apoptosis showed that T24 cells were responders for
S4-Jena and Tice BCG, while Cal29 cells were responders
for S4-Jena only. The authors concluded that S4-Jena
strain may represent an effective therapeutic agent for
NMIBC [29].
A clinical study comparing BCG Tice and Connaught in
Switzerland [16], showed more than two-fold morecommon recurrences in patients treated with BCG Tice
than Connaught, prompting the authors to wonder about
the worldwide clinical impact on patients, and economic
burden on healthcare systems of different countries. They
went on to assess the global distribution of different BCG
strains used to treat bladder cancer. They obtained infor-
mation from 55% (140/252) of all countries (72% of global
population and 98% of industrialized countries) and showed
that BCG Tice and BCG Connaught were the most com-
monly used BCG strains worldwide (each used in 54 coun-
tries), followed by BCG RIVM (in 28 countries), Pasteur (in
17 counties), Danish (in 6 countries), China and Tokyo
(in one country each). The authors concluded that based
on the observed difference in tumor recurrence for the
widely use BCG Tice and Connaught in NMIBC, a large
proportion of patients are at risk of an inferior treatment.
Clearly, no presumptions can be made regarding the
clinical efficacy and safety of an individual BCG strain
unless proven by an induction and maintenance protocol
in the clinical setting.
Conclusions
Our study is the first to show the clinical efficacy and
tolerability of BCG-RIVM strain in the management of
high risk NMIBC when given in a schedule of induction
with monthly instillations as maintenance for one year. Our
maintenance protocol, achieved equivalent recurrence-free,
progression-free, disease specific survival and overall sur-
vival to the more intense three-years SWOG protocol.
Only head to head comparative trials between different
BCG strains in the treatment of patients with high risk
NMIBC can determine their relative clinical efficacy, tox-
icity, appropriate dose, and ideal maintenance protocol for
the individual BCG strain.
Abbreviations
BCG: Bacillus Calmette-Guerin; CI: Confidence interval; CIS: Carcinoma-in-situ;
MMC: Mitomycin C; RFS: Recurrence-free survival; SE: Standard error;
SWOG: South West Oncology Group; TCC: Transitional cell carcinoma;
TURBT: Transurethral resection of bladder tumor; NMIBC: Non-muscle
invasive bladder cancer.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
NBF: Enrollment of patients, carried out endoscopic procedures and other
surgical operations, follow-up of patients and drafted the manuscript. RG:
Carried out intravesical BCG instillations, participated in endoscopy procedures
and other surgical operations, follow-up of patients, collection of data and
participated in the manuscript drafting. MA: Participated in intravesical BCG
instillations, collection of data, follow-up of patients and participated in the
discussion of the manuscript draft. All authors read and approved the final
manuscript.
Acknowledgements
The authors would like to extend their greatest appreciation and thanks to:
Miss Dalia Al-Rimawi, Senior Statistical programmer, at King Hussein cancer
Center, (e-mail: drimawi@KHCC.JO), for helping in organizing the clinical data
and for the detailed statistical analysis.
Farah et al. BMC Urology 2014, 14:11 Page 11 of 11
http://www.biomedcentral.com/1471-2490/14/11Author details
1From the department of surgery, section of Uro-oncology, King Hussein
Cancer Center, Amman, Jordan. 2Section of Uro-oncology, King Hussein
Cancer Center, Amman, Jordan. 3Department of Surgical oncology, Amman,
Jordan.
Received: 7 November 2013 Accepted: 6 January 2014
Published: 27 January 2014References
1. Kresowik TP, Griffith TS: Bacillus Calmette-Guerin immunotherapy for
urothelial carcinoma of the bladder. Immunotherapy 2009, 1(2):281–288.
2. Fabian S, Rodrigo Q, de Medina SGD, Laurent S, Abbou CC, Chopin DK:
Bacille Calmette-Guerin (BCG) for the treatment of superficial bladder cancer.
a critical analysis of 25 years' experience with various therapeutic schedules.
www.urofrance.org/fileadmin/medias/sncuf/lettre..../25-ans-bcg.pdf.
3. Han RF, Pan JG: Can intravesical bacillus Calmette-Guerin reduce
recurrence in patients with superficial bladder cancer: a meta-analysis of
randomize trials. Urology 2006, 67(6):1216–1223.
4. Per-Uno M, Per-Uno M, Sylvester RJ, Crawford DE, Martin F, Susanne K,
Erkki R, Eduardo S, Di Stasi SM, Alfred Witjes J: An individual patient data
meta-analysis of the long-term out cone of randomized studies comparing
intravesical mitomycin C versus bacillus calmette-guerin for
non-muscle-invasive bladder cancer. Eur Urol 2009, 56:247–256.
5. Sylvester RJ, van der Meijden AP, Lamm DL: Intravesical bacillus Calmette-
Guerin reduces the risk of progression in patients with superficial
bladder cancer: a meta-analysis of the published results of randomized
clinical trials. J Urol 2002, 168:1964–1970.
6. Vegt PDJ, Alfred Witjes J, Witjes WPJ, Doesburg WH, Debruyne FMJ, van der
Meijden APM: A randomize study of intravesical mitomycin C, bacillus
Calmette-Guerin Tice and bacillus Calmette-Guerin RIVM treatment in
pTa-pT1 papillary carcinoma and carcinoma in situ of the bladder. J Urol
1995, 153:929–933.
7. Witjes WP, Witjes JA, Oosterhof GO, Debruyne MJ: Update on the Dutch
cooperative trial: mitomycin versus bacillus Calmette-Guerin- Tice versus
bacillus Calmette-Guerin RIVM in the treatment of patients with pTa-pT1
papillary carcinoma and carcinoma in situ of the urinary bladder. Dutch
south east cooperative urological group. Semin Urol Oncol 1996,
14(1 Suppl 1):10–16.
8. Akaza H, Hinotsu S, Aso Y, Kakizoe T, Bladder Cancer BCG, Group S: Bacillus
Calmette-Guerin treatment of existing papillary bladder cancer and
carcinoma in situ of the bladder. Four year results. Cancer 1995,
75:552–559.
9. Lamm DL, Blumenstein BA, Crissman JD, Montie JE, Gottesman JE, Lowe BA,
Sarosdy MF, Bohl RD, Barton Grossman H, Beck TM, Liemert JT, David
Crawford E: Maintenance bacillus Calmette-Guerin immunotherapy for
recurrent TA, T1 and carcinoma in situ transitional carcinoma of the
bladder: a randomized southwest oncology group study. J Urol 2000,
163:1124–1129.
10. Lamm DL: Efficacy and safety of bacillus Calmette-Guerin immunotherapy
in superficial bladder cancer. Clin Infect Dis 2000, 31(Supplement 3):S86–S90.
10.1086/314064.
11. Lamm D: Improving patient outcomes: Optimal BCG treatment regimen
to prevent progression in superficial bladder cancer. Eur Urol Suppl 2006,
5:654–659.
12. Lamm DL: Preventing progression and improving survival with BCG
maintenance. Eur Urol 2000, 37(suppl 1):9–15.
13. Christine G, Hugh M, Muhammad Shamim K, Lewis DJM: BCG
immunotherapy for bladder cancer- the effect of sub-strain difference.
Nat Rev Urol 2013, 10:580–588. published on line 17 September 2013;
doi:10.1038/nrurol.2013.194.
14. Gsponer JR, Bornand D, Bachmann A, Albert ML, Thalmann GN, Rentsch CA:
Intravesical treatment of non-muscle invasive bladder cancer: global
distribution of BCG strains and potential health economic impact of strain
differences - Switzerland as an example. Freitag 2012:13:00–13:05.
15. Herr HW, Dalbagni G: Defining bacillus Calmette-Guerin refractory superficial
bladder tumors. J Urol 2003, 169:1706–1708. Pub-Med.
16. Herr HW: Transurethral resection and intravesical therapy of superficial
bladder tumors. In The Urology Clinics of North America, Volume 18. Edited
by Fair WR. Philadelphia: WB Saunders; 1991:525–8.17. In-Chang C, Kim EKy, Jae Young J, Ho Kyung S, Jinsoo C, Weo Seo P,
Kang Hyun L: Adjuvant intravesical instillation for primary T1G3 bladder
cancer: BCG versus MMC in Korea. Anticancer Res 2012, 32:1493–1498.
18. Koo Han Y, Tea Joon L, Sung-Goo C: Monthly intravesical bacillus
Calmette-Guerin maintenance therapy for non-muscle-invasive bladder
cancer: 10-year experience in a single institute. Exp Ther Med 2012,
3(2):221–225.
19. Friedrick MG, Pichlmeier U, Schwaibold H, Conrad S, Huland H: Long-term
intravesical adjuvant chemotherapy further reduces recurrence rate
compare with short-term intravesical chemotherapy and short-term
therapy with bacillus Calmette-Guerin (BCG) in patients with
non-muscle-invasive bladder carcinoma. Eur Urol 2007, 52:1123–1130.
20. Askeland EJ, Newton MR, O'Donnell MA, Yi L: Bladder cancer
immunotherapy: BCG and beyond. Adv Urol 2012, 2012:181987.
21. Badalament RA, Herr HW, Wong GY, Gnecco C, Pinsky CM, Whitmore WF,
Fair WR, Oettgen HF: A prospective randomized trial of maintenance
versus nonmaintenance intravesical bacillus Calmette-Guerin therapy of
superficial bladder cancer. J Clin Onco 1987, 5:441–449.
22. Palou J, Laguna P, Millan-Rodriguez F, Hall RR, Salvador-Bayarri J, Vincente-
Rodriguez J: Control group and maintenance treatment with bacillus
Calmette-Guerin for carcinoma in situ and/or high grade bladder tumors.
J Urol 2001, 165(5):1488–1491.
23. Strock V, Dotevall L, Sandberg T, Gustafsson CK, Holmang S: Late bacille
Calmette-Guerin infection with a large focal urinary bladder ulceration as a
complication of bladder cancer treatment. BJU Int 2011, 107(10):1592–1597.
24. Gallagher BL, Joudi FN, Maymi JL, O'Donnell MA: Ipact of previous bacille
Calmette-Guerin failure pattern in subsequent response to bacille
Calmette-Guerin plus interferon intravesical therapy. Urology 2008,
71(2):297–301.
25. Lambert EH, Pierorazio PM, Olsson CA, Benson MC, MckKiernan JM, Poon S:
The increase use of intravesical therapies for stag T1 bladder cancer
coincides with decreasing survival after cystectomy. BJU Int 2007,
100:336.
26. Michael P, Florent G, Delphine A-O, Djillali S, Bernard D, Marc Z: Intravesical
bacillus Calmette-Guerin therapy for stage T1 grade 3 transitional cell
carcinoma of the urinary bladder: recurrence, progression and survival in
a study of 57 patients. J Urol 2003, 169:2110–2212.
27. Pansadoro V, Emiliozzi P, Depaula F, Scarpone P, Pizzo M, Federico G,
Martini M, Pansadoro A, Stenberg CN: High grade superficial (G3t1)
transitional cell carcinoma of the bladder treated with bacillus
Calmette-Guerin (BCG). J Exp Clin Cancer Res 2003, 22(4 Suppl):223–227.
28. Mejiden APMvd, Steerenberg PA, de Jong WH, Bogman MJJ, Feitz WFJ,
Hendriks BT, Debruyne FMJ, Ruitenberg EJ: The effect of intravesical and
intra-dermal application of a new BCG on dog bladder. Urol Res 1986,
14(4):207–210.
29. Katja S, Martin F, Thomas S, Inge-Marie H, Eberhard S: BCG strain S4-Jena:
an early BCG strain is capable to reduce the proliferation of bladder
cancer cells by induction of apoptosis. Canc Cell Int 2010, 10:21.
doi:10.1186/1471-2490-14-11
Cite this article as: Farah et al.: Treatment efficacy and tolerability of
intravesical Bacillus Calmette-Guerin (BCG) - RIVM strain: induction and
maintenance protocol in high grade and recurrent low grade
non-muscle invasive bladder cancer (NMIBC). BMC Urology 2014 14:11.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
